MYC and cancer: For example, as an ibrutinib-venetoclax nonresponder, Patient B was clearly separated from the ibrutinib-sensitive patients, particularly in the manifestation of cancer hallmarks such as OXPHOS, mTORC1, G2/M checkpoint, and MYC.